Lancet Rheumatology最新文献_第2页

Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5 《柳叶刀风湿病杂志2025》修正；2月27日在线发表。https://doi.org/10.1016/s2665 - 9913(24) 00348 - 5。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-27 DOI: 10.1016/S2665-9913(25)00096-7

引用次数: 0

Correction to Lancet Rheumatol 2020; 2: e99–109 《柳叶刀风湿病ol 2020》修正；2: e99 - 109。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-27 DOI: 10.1016/S2665-9913(25)00097-9

引用次数: 0

Correction to Lancet Rheumatol 2020; 2: e418–27 《柳叶刀风湿病ol 2020》修正；2: e418-27。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-27 DOI: 10.1016/S2665-9913(25)00098-0

引用次数: 0

CAR T-cell therapy in autoimmune diseases: where are we and where are we going? 自体免疫疾病中的CAR - t细胞疗法：我们在哪里，我们将走向何方？

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-26 DOI: 10.1016/S2665-9913(24)00377-1

Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac

{"title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","authors":"Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac","doi":"10.1016/S2665-9913(24)00377-1","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00377-1","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-based therapies developed for the treatment of haematological malignancies have recently been repurposed to treat refractory systemic autoimmune diseases. In this Review we critically discuss the current data available on the use of CAR-based therapy in systemic autoimmune diseases, the current challenges, and the potential next steps toward their implementation into clinical practice. Beyond the targeting of B cells via CD19, we discuss the advantages and potential pitfalls of targeting plasma cells (B-cell Maturation Antigen or CD138) and other non-immune targets, such as fibroblast activated protein, and of aiming to restore immune homeostasis using CAR T regulatory cells. Crucial points need to be addressed for CAR-based therapy to become a viable treatment option for patients with systemic autoimmune diseases.</p>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research in Brief 研究简介

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-24 DOI: 10.1016/S2665-9913(25)00072-4

Jennifer Thorley

引用次数: 0

Improving polymyalgia rheumatica care: considerations for routine vascular ultrasound in clinical practice. 改善风湿性多肌痛的护理：常规血管超声在临床实践中的考虑。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-17 DOI: 10.1016/S2665-9913(25)00031-1

Max Yates, Charlotte Davies, Alexander James MacGregor

引用次数: 0

JIA care under the microscope 显微镜下JIA护理。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-17 DOI: 10.1016/S2665-9913(25)00073-6

The Lancet Rheumatology

引用次数: 0

Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome 2023年EULAR-ACR抗磷脂综合征分类标准的诊断、研究和现实影响

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-08 DOI: 10.1016/S2665-9913(24)00396-5

Karen Schreiber PhD , Silvia Aguilera PhD , Prof Olga Amengual PhD , Prof Hannah Cohen MD , Prof Danieli Castro Oliveira De Andrade MD PhD , Prof Alí Duarte-García MD , Prof Maria Gerosa PhD , Prof Catherine Nelson-Piercy MD , Massimo Radin MD PhD , Prof Luigi Raio MD , Prof Savino Sciascia PhD

{"title":"Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome","authors":"Karen Schreiber PhD , Silvia Aguilera PhD , Prof Olga Amengual PhD , Prof Hannah Cohen MD , Prof Danieli Castro Oliveira De Andrade MD PhD , Prof Alí Duarte-García MD , Prof Maria Gerosa PhD , Prof Catherine Nelson-Piercy MD , Massimo Radin MD PhD , Prof Luigi Raio MD , Prof Savino Sciascia PhD","doi":"10.1016/S2665-9913(24)00396-5","DOIUrl":"10.1016/S2665-9913(24)00396-5","url":null,"abstract":"<div><div>The role of classification criteria is particularly important in rheumatic diseases compared with other medical disorders, as the complexity and overlapping symptoms of these conditions make diagnosis challenging. Moreover, the absence of established diagnostic criteria further complicates diagnosing patients. Classification criteria can assist health-care professionals and patients as a diagnostic aid. However, classification criteria are developed for research purposes to standardise populations in clinical trials and observational studies of rheumatic diseases and not for diagnosing patients. Introduction of the 2023 American College of Rheumatology−European Alliance of Associations for Rheumatology (ACR–EULAR) antiphospholipid syndrome classification criteria underscores the important distinction between meeting these criteria and being diagnosed with the condition—a differentiation essential in both clinical practice and research. Although the 2023 ACR–EULAR antiphospholipid syndrome classification criteria improved precision in classification of pregnant individuals with antiphospholipid syndrome, which ultimately should lead to better outcomes and care for these patients, the updated criteria should not be used as diagnostic criteria in routine clinical practice. In this Personal View, we examine the possible effect of the 2023 ACR–EULAR antiphospholipid syndrome classification criteria, with a particular focus on the pregnancy-related aspects of the syndrome.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e368-e376"},"PeriodicalIF":15.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases 风湿病b细胞靶向治疗的发展和轨迹

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-06 DOI: 10.1016/S2665-9913(24)00338-2

Lucy Marie Carter PhD , Prof Michael R Ehrenstein PhD FRCP , Prof Edward M Vital PhD

{"title":"Evolution and trajectory of B-cell targeted therapies in rheumatic diseases","authors":"Lucy Marie Carter PhD , Prof Michael R Ehrenstein PhD FRCP , Prof Edward M Vital PhD","doi":"10.1016/S2665-9913(24)00338-2","DOIUrl":"10.1016/S2665-9913(24)00338-2","url":null,"abstract":"<div><div>Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be specifically therapeutically targeted through depletion and have the only therapy with a routinely available flow cytometric biomarker of treatment. Since first use and subsequent licensing for rheumatoid arthritis, rituximab has had a transformative impact on patients globally and across the rheumatic diseases. Further insights from B-cell-activating factor (BAFF) blockade with belimumab in systemic lupus erythematosus have followed. Examination of B-cell depletion, clinical outcomes, and re-emergent disease after treatment have deepened our understanding of the identity, detailed phenotype, biology, and kinetics of the B-cell subsets that are central to disease. This Review reflects on 20 years of clinical and translational insights drawn from B-cell targeted therapies for adult autoimmune rheumatic diseases, and highlights how these therapies have informed an exciting new era of future therapeutic developments.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e355-e367"},"PeriodicalIF":15.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unwarranted escalation of care for back pain: a dilemma for emergency health services 无根据的背部疼痛护理升级：紧急卫生服务的困境。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2025-03-04 DOI: 10.1016/S2665-9913(25)00059-1

Simon Vella , Peter Youssef , Chris Maher , Gustavo Machado

引用次数: 0